In the Claims

Claims 1-14 (Cancelled)

Claim 15 (New): A method for reducing adhesion formation, comprising administering a therapeutic formulation comprising TIMP-1 antibodies, or Fab fragments thereof, to a patient at risk of adhesion formation, wherein the therapeutic formulation is administered in an amount effective to reduce adhesion formation.

Claim 16 (New): The method of claim 15, wherein the therapeutic formulation comprises TIMP-1 antibodies, and wherein the TIMP-1 antibodies are monoclonal antibodies.

Claim 17 (New): The method of claim 15, wherein the therapeutic formulation comprises TIMP-1 antibodies, and wherein the TIMP-1 antibodies are polyclonal antibodies.

Claim 18 (New): The method of claim 15, wherein the therapeutic formulation further comprises a suitable carrier.

Claim 19 (New): The method of claim 18, wherein the carrier is hyaluronic acid.

Claim 20 (New): The method of claim 15, wherein the adhesion is a surgical adhesion.

Claim 21 (New): The method of claim 15, wherein the adhesion is caused by trauma within the peritoneal cavity.

Claim 22 (New): The method of claim 15, wherein the adhesion is caused by inflammation within the peritoneal cavity.

Claim 23 (New): The method of claim 15, wherein the adhesion is a peritoneal adhesion.

Claim 24 (New): The method of claim 15, wherein the adhesion is a surgical, peritoneal adhesion.

Claim 25 (New): The method of claim 15, wherein the adhesion is a surgical adhesion of intra-peritoneal tissue selected from the group consisting of parietal peritoneum, uterus, fallopian tube, ovary, bowel, and omentum.

Claim 26 (New): A method for reducing surgical adhesion formation within the peritoneal cavity, comprising administering a therapeutic formulation comprising TIMP-1 antibodies, or Fab fragments thereof, to a patient at risk of surgical adhesion formation, wherein the therapeutic formulation is administered in an amount effective to reduce surgical adhesion formation within the peritoneal cavity.